Capricor Therapeutics
William J. Morrison IV, PhD has a diverse work experience. In 2016, they worked as a Research Intern at the El Paso County Coroner's Office Forensic Toxicology Laboratory. During this time, they conducted research validation with deidentified whole blood samples and shadowed assistant forensic toxicologists in routine ELISA screenings and drug conformation in post mortem cases.
In 2017, William joined the American Chemical Society as a Student Affiliate Member and continued in this role until 2023.
Also in 2017, William joined Florida International University where they held multiple roles. From August 2017 to April 2018, they served as a Graduate Teaching Assistant for the General Chemistry II Lab. From May 2018 to April 2021, they worked as a Graduate Research Assistant. Additionally, from May 2021 to March 2023, they worked as a Graduate Teaching Assistant for the Analytical Chemistry Lab.
In 2021, William became a Student Affiliate Member of the Society of Forensic Toxicologists, Inc. and held this position until March 2023.
Most recently, in 2023, William joined Capricor Therapeutics, Inc. as a Scientist, where they are currently employed.
William J. Morrison IV, PhD, has a strong background in chemistry with a focus on analytical chemistry. William J. pursued their education at several reputable institutions. From 2013 to 2017, William attended the University of Colorado Colorado Springs, where they obtained a Bachelor of Science (BS) degree in Chemistry. Following this, they enrolled at Florida International University, where they completed a Master of Science (MS) degree in Chemistry from 2017 to 2020. Their academic journey continued at Florida International University, where they pursued a Doctor of Philosophy (PhD) in Analytical Chemistry from 2017 to 2023. Overall, William's education history showcases a progressive and in-depth understanding of chemistry, specifically analytical chemistry.
This person is not in any offices
Capricor Therapeutics
1 followers
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases.